Epilepsy associated depression
Conditions
Interventions
Epilepsy combined with depression group:No intervention
Temporal lobe epilepsy group:No intervention
Healthy control group:No intervention
Sponsors
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-65 years, no gender restriction; 2. Meet the classic 1989 International League Against Epilepsy classification criteria for epilepsy and epileptic syndromes: (1) Clinical seizure symptoms suggesting that the epileptogenic lesion is located in the temporal lobe; (2) Electroencephalograph (EEG) during the seizure or interictal period suggests that the epileptic lesion is located in or originates from the temporal lobe; (3) No antidepressant medication was received; 3. The diagnostic criteria for depressive episodes met the classification and related diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV); 4. Hamilton Depression Scale (HAMD) 17-item score >=17 points and < 24 points; 5. All subjects or their guardians gave informed consent and were willing to participate and sign an informed consent form. Single patients with temporal lobe epilepsy with a current diagnosis should meet conditions 1 and 2. Patients with temporal lobe epilepsy with depression should have a current diagnosis that meets conditions 1, 2, 3, and 4; a diagnosis of concomitant depressive seizures (both initial and recurrent) without medication; and a diagnosis of epilepsy that predates the initial depressive seizure by more than six months. Normal control group: normal healthy volunteers. No epileptic seizures and depressive episodes occurred within six months.
Exclusion criteria
Exclusion criteria: 1. Patients with serious medical diseases (including cardiovascular, digestive, urological, immune, respiratory, etc.); 2. Patients with inflammatory and immune system diseases; 3. Patients with a history of substance abuse; 4. Patients with other psychiatric diseases, such as schizophrenia, bipolar disorder, eating disorders, etc.; 5. Patients who have used cytokine-like drugs or drugs that affect cytokines and such and other drugs that interfere with Tryptophan metabolic pathway drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| indoleamine 2,3-dioxygenase;kynurenine;tryptophan;quinolinic acid;kynurenic acid;3-hydroxyanthranilic acid;3-hydroxykynurenine;Intestinal flora;microRNA;Cortisol;Biomarkers of brain injury (e.g., GFAP, NfL, p-Tau 181, and p-Tau 217);Lipid Metabolites;Peripheral Blood Immune Cells; | — |
Countries
China
Contacts
Public ContactLun Cai
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Outcome results
None listed